S-1/A: DiamiR Biosciences Corp. Files Amendment No. 2 to Form S-1, Eyes NASDAQ Listing

DiamiR Biosciences Corp. amends its S-1 registration statement, aiming for a NASDAQ listing to advance its molecular diagnostics for neurodegenerative diseases.

Summary

• DiamiR Biosciences Corp. has filed a pre-effective Amendment No. 2 to its Form S-1 registration statement with the SEC.
• The company is pursuing an initial public offering (IPO) to list its common stock on the NASDAQ Capital Market under the ticker symbol DIMR.
• The offering includes shares of common stock and resale shares from selling shareholders.
• DiamiR is an emerging growth company focused on developing blood-based tests for neurodegenerative diseases like Alzheimer's and Parkinson's.
• The company's co-founders currently own and control a significant portion of the outstanding common stock.
• The company intends to use the proceeds from the offering for working capital, to support the development and launch of its first test, CogniMIR, and other lab-developed tests (LDTs), for marketing and sales, and to establish or acquire CLIA lab capabilities.
• The company has a limited operating history and has incurred net losses in each year since its inception, including net losses of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing an IPO and has promising technology, it also faces significant financial challenges and risks, including a limited operating history, net losses, and substantial doubt about its ability to continue as a going concern.

Positives

• The company is developing innovative blood-based tests for early detection and monitoring of neurodegenerative diseases.
• The company has established collaborative relationships with leading clinical research organizations.
• The company has a strong intellectual property portfolio with 51 issued patents.
• The company has received grants from the National Institutes of Health and private foundations.

Negatives

• The company has a limited operating history and has incurred net losses in each year since its inception.
• The company has not completed development of any product candidate and has not generated any revenues from product sales.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to generate revenue and achieve profitability is dependent on its ability to complete the development of its product candidates, obtain necessary regulatory approvals, and have its products under development manufactured and successfully marketed.
• The company faces significant competition from a number of different sources.
• The company's operations are dependent upon its key personnel.
• The company will incur increased costs as a result of being a public company.
• The company has identified material weaknesses in its internal control over financial reporting which, if not corrected, could affect the reliability of its financial statements, and have other adverse consequences.
• The company's principal stockholders and management own a significant percentage of its capital stock and are able to exert a controlling influence over its business affairs and matters submitted to stockholders for approval, including a change in its corporate control even if its other shareholders wanted it to occur.
• If researchers, clinicians and healthcare administrators do not adopt the company's screening and diagnostic products, the company will not achieve future sales growth.
• New product development and clinical validation involves a lengthy and complex process, and the company may be unable to commercialize CogniMIR or any other products it may develop on a timely basis, or at all.
• The company relies on a sole supplier for some of the materials used in its tests and services, and it may not be able to find replacements or transition to alternative suppliers in a timely manner.
• The company may now or in the future be subject to laws and regulations relating to laboratory testing, which could materially adversely impact its ability to offer its products or services.
• The regulatory processes applicable to the company's products and operations are expensive, time-consuming, and uncertain and may prevent the company from obtaining required authorizations for the commercialization of its products.
• The company may be unable to protect or obtain proprietary rights.
• Intellectual Property infringement claims by other companies could result in costly disputes and could limit the company's ability to sell its products.
• If product liability lawsuits are successfully brought against the company, it may incur substantial liabilities and may have to limit or cease sales of its products.
• There is no market for the securities offered hereby.
• The market price of the Common Stock will fluctuate significantly in response to a variety of factors, some of which are beyond the Company's control.
• Our management will have broad discretion in how we use the net proceeds of this offering and might not use them effectively.
• When this registration statement becomes effective, there will be a significant number of shares of Common Stock eligible for sale, which could depress the market price of such stock.
• Future sales of our securities may affect the market price of the Common Stock and result in material dilution.
• Any market that develops in shares of our common stock will be subject to the penny stock regulations and restrictions, which could impair liquidity and make trading difficult.
• We have established preferred stock which can be designated by our Board of Directors without shareholder approval.
• Anti-takeover provisions in our Certificate of Incorporation and our Bylaws, as well as provisions of Delaware law, might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Future Outlook

The company expects to incur increased expenses as it conducts its clinical studies and creates additional infrastructure to develop and launch CogniMIR and support operations as a public company. As a result, the company expects to continue to incur net losses and negative cash flows for the foreseeable future.

Management Comments

• Management believes this capital is insufficient to fund the Companys operations for the next twelve months.
• Management does not anticipate that the Companys existing working capital alone will be sufficient to fund its operations through the successful development and commercialization of products.

Industry Context

The document highlights the increasing focus on early detection and intervention in neurodegenerative diseases, particularly Alzheimer's, and the growing market for diagnostic tools and biomarkers. It also acknowledges the competitive landscape and the need for cost-effective and non-invasive testing methods.

Comparison to Industry Standards

• The document mentions several companies and academic groups working on biomarker tests for early detection of AD, including Quanterix, C2N Diagnostics, ALZPath, Cognoptix, Eli Lilly, LabCorp, NanoSomiX, NeuroTrack, Esya Labs, Brain Spec, Cogni.Dx, Roche, and Quest Labs.
• It notes that Quanterix, C2N Diagnostics, and Quest Labs have launched commercial LDTs for AD based on select protein biomarkers (A b 42/40, p-Tau217, and p-Tau181).
• The document states that DiamiR is currently not aware of any miRNA blood-based tests for early detection of AD on the market.

Related Party Transactions

• On March 15, 2023, the company issued convertible promissory notes to Samuil R. Umansky and Kira Sheinerman.
• On October 10, 2023, the company amended and restated Kira Sheinerman's note.
• On March 30, 2023, the company entered into an insider stock purchase agreement with Kira Sheinerman.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Job security dependent on the company's ability to raise capital and achieve profitability.
• Customers: Access to innovative diagnostic tests for neurodegenerative diseases.
• Suppliers: Potential for increased business as the company expands its operations.
• Creditors: Increased risk due to the company's financial challenges.

Next Steps

• Initiate a clinical validation study in late 2024 from samples that have already been collected and are available to us from our freezer stock.
• Implement a robust commercial and publication strategy focused on securing coverage from Medicare and private insurance payors.

Key Dates

Keywords

molecular diagnostics, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, microRNAs, CogniMIR, IPO, NASDAQ, LDT, biomarkers